Company: INMB
Filing Date: 2025-08-07
Form Type: 8-K
Source: 0001213900-25-073089
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01. Other Events.

On August 4, 2025, the
Company issued a press release announcing that that its Phase I/II trial (the “ CaRe PC” trial) of INKmune™ for men with
metastatic castration-resistant prostate cancer has met its primary and secondary endpoints and is now closed to further enrollment.

A copy of the press release
is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits